ROG has been the subject of several other reports. Societe Generale set a CHF 190 price objective on Roche and gave the company a sell rating in a report on Monday, January 15th. JPMorgan Chase & Co. reiterated a buy rating and issued a target price on shares of Roche in a report on Thursday, November 2nd. Liberum Capital set a CHF 279 target price on shares of Roche and gave the stock a buy rating in a report on Wednesday, November 22nd. Barclays set a CHF 305 price target on Roche and gave the stock a buy rating in a research note on Thursday, December 21st. Finally, Goldman Sachs Group set a CHF 325 price target on Roche and gave the stock a buy rating in a research note on Wednesday, December 13th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of CHF 255.05.
Roche (VTX ROG) traded up CHF 0.05 during mid-day trading on Monday, hitting CHF 228.25. The company had a trading volume of 2,210,000 shares, compared to its average volume of 2,130,000. The company has a market capitalization of $197,010.00 and a P/E ratio of 22.73. Roche has a 12-month low of CHF 214.30 and a 12-month high of CHF 273.
ILLEGAL ACTIVITY NOTICE: “Jefferies Group Analysts Give Roche (ROG) a CHF 290 Price Target” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://ledgergazette.com/2018/03/14/roche-rog-pt-set-at-chf-290-by-jefferies-group.html.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.